Rd-Biotech company information, Employees & Contact Information

Takeda turns to AI drug designer for $1B biobucks deal after whittling down R&D focus Fierce Biotech

Amgen to build $600M R&D site, hire hundreds in California Fierce Biotech

The top 10 pharma R&D budgets for 2024 Fierce Biotech

AstraZeneca details $2.5B investment in China's political center, funding R&D center, biotech pacts Fierce Biotech

Novo Nordisk finds Deep Apple ripe for obesity R&D, inking $812M deal to go beyond incretins Fierce Biotech

Fresh off $120M raise, AI-powered Terray is teaming up with Gilead in multi-pronged R&D pact Fierce Biotech

Moderna targets $1.1B in R&D spending cuts, drops 5 programs amid profitability pressures Fierce Biotech

'Stunning' 4% yearly rise in R&D share has emerging biopharma dominating pipeline Fierce Biotech

A closer look at pharma's top R&D budgets Fierce Biotech

Sanofi becomes latest pharma to hold fire on UK R&D investments as funding fallout continues Fierce Biotech

The 10 highest value R&D projects in biopharma Fierce Biotech

The top 10 pharma R&D budgets for 2023 Fierce Biotech

The most valuable R&D projects? You guessed it: obesity Fierce Biotech

Merck executes its own Brexit, moving all R&D operations out of UK Fierce Biotech

Novo Nordisk's new Boston-area campus reflects 'competitive' R&D growth, and not just for GLP-1s Fierce Biotech

'Not a cost-cutting exercise': Novo Nordisk CSO explains rationale behind pharma's R&D shake-up Fierce Biotech

GSK shuffles R&D as research head John Lepore heads out the door Fierce Biotech

Top 10 pharma R&D budgets in 2022 Fierce Biotech

CSL to lay off up to 15% of workforce, cut R&D costs and spin out vaccine unit Fierce Biotech

Eli Lilly unwraps $700M nucleic acid R&D center in Boston Seaport, opens doors to biotechs Fierce Biotech

CSL trims R&D team, shifts focus toward external opportunities Fierce Biotech

Gilead-backed study warns IRA price negotiations could hit R&D harder than expected Fierce Biotech

Black Friday for Spectrum as FDA lung cancer rejection prompts 75% cut to R&D workforce Fierce Biotech

The obesity pipeline was 'late breaking.' Here's what the R&D landscape looks like now Fierce Biotech

Top 10 pharma R&D budgets in 2021 Fierce Biotech

Immunovant narrows R&D focus as Roivant execs take CEO, CFO posts Fierce Biotech

Takeda confirms fallout from gene therapy R&D refocus: up to 186 layoffs Fierce Biotech

Sanofi inks pact with Canadian tech company to bring AI to R&D Fierce Biotech

Top 5 highest paid biopharma R&D executives in 2022 Fierce Biotech

Ipsen dives into $1.8B Skyhawk pact to fire up RNA modulator R&D Fierce Biotech

GSK telegraphs 'very limited number' of job cuts amid R&D investment spree Fierce Biotech

UPDATE: J&J to shut down massive Bay Area R&D facility less than 18 months after opening it Fierce Biotech

Pfizer CEO says R&D is the 'lifeblood that fuels us' as spending revs up post-COVID Fierce Biotech

CSL Behring unveils its largest R&D site in founder's hometown, slated to open before the end of the year Fierce Biotech

Steeling itself for undruggable challenges, Astellas inks $180M deal to bolster mitochondria R&D unit Fierce Biotech

Google Cloud 'can't wait to see what's next' as Servier extends AI drug R&D pact Fierce Biotech

Taysha lays off 35% of staff, narrows R&D focus to keep funding its top gene therapies Fierce Biotech

Big Pharma-backed antibiotic R&D fund lands another $140M, bringing total haul above $1B Fierce Biotech

Amicus' gene therapy SPAC merger folds, turning pipeline and R&D into target of $400M in cuts Fierce Biotech

Gilead lays off 72 workers in Seattle, plans to shutter R&D support site Fierce Biotech

Pfizer pivots from early-stage rare disease R&D, shifting to external innovation and putting assets up for sale Fierce Biotech

Big Pharma's ROI for drug R&D saw 'welcome' rebound in 2023: report Fierce Biotech

Boehringer OKs $100M biobucks deal for hearing loss R&D project Fierce Biotech

With first microbiome drug approved, Seres slims R&D efforts and workforce Fierce Biotech

Amgen cuts lupus programs for futility hours after Lilly officially walks away from one, too Fierce Biotech

The top 10 pharma R&D budgets in 2018 Fierce Biotech

Lilly puts two-thirds of midphase cancer pipeline up for sale in major shake-up of R&D priorities Fierce Biotech

Sanofi punts 38 R&D projects to narrow pipeline focus Fierce Biotech

BenevolentAI, cruel R&D: AI-enabled drug flunks midphase eczema trial to dent deal plans Fierce Biotech

Lilly to shutter U.S., China R&D centers Fierce Biotech

Novartis pivots Shanghai R&D site from early discovery to development Fierce Biotech

AstraZeneca converges with Verge's AI tech in $42M neurodegenerative disease R&D pact Fierce Biotech

J&J to spin off Actelion R&D unit into new biotech in major M&A deal Fierce Biotech

Meet Neumora, Arch's $500M, Amgen-partnered play for the targeted future of neuroscience R&D Fierce Biotech

GSK, under pressure to perform, pens $2.2B deal with Alector focused on neuro R&D, Alzheimer's Fierce Biotech

Pfizer is shuttering another U.K. R&D outpost, ditching 120 jobs Fierce Biotech

Amgen moves R&D jobs from HQ to Cambridge and San Francisco as rolling reorganization continues Fierce Biotech

GSK allies with Innovax for COVID-19 vaccine R&D project Fierce Biotech

The top 10 global R&D institutes Fierce Biotech

BenevolentAI's Proximagen buy creates first AI firm capable of entire drug R&D Fierce Biotech

20 Big Pharma and biotech mobile apps - 2013 Fierce Biotech